Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of KSI-301 versus aflibercept in neovascular age-related macular degeneration
MOH_2019-09-02_007379Phase 2Not yet recruiting
- Sponsor
- Kodiak Sciences
- Start
- Aug 2019
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in exudative macular degeneration comparing KSI-301 with aflibercept (2 arms). Primary endpoint: Mean change in BCVA from Day 1 to Year 1. Planned start Aug 2019; status: not yet recruiting.
02
Drugs
tarcocimab tedromeraflibercept
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on MOH_2019-09-02_007379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-09-02_007379.